07:00 , Sep 12, 2011 |  BioCentury  |  Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

Anthrax Immune Globulin regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Emergent BioSolutions' Anthrax Immune Globulin (AIG) to treat inhalation anthrax disease. The anthrax immune globulin, which was developed...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

Anthrax Immune Globulin: Phase I/II started

Emergent BioSolutions began a double-blind, dose-escalation, U.S. Phase I/II trial to compare 3 dose levels of a single IV infusion of AIG vs. Gamunex immune globulin from Talecris Biotherapeutics Inc. (Research Triangle Park,...
07:00 , May 12, 2008 |  BC Week In Review  |  Company News

Emergent BioSolutions, VaxGen deal

Emergent acquired VaxGen’s rPA102 anthrax vaccine and related assets for $2 million up front and up to $8 million in milestones, plus royalties. Emergent said the acquisition diversifies its anthrax portfolio. Emergent’s BioThrax ...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Company News

Emergent BioSolutions, National Institutes of Health, U.S. Department of Health and Human Services infectious news

EBS received a three-year contract from HHS for up to $447.7 million for the company's BioThrax anthrax vaccine. The contract includes $400 million to deliver 18.8 million doses for the strategic national stockpile, $34...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Clinical News

Anthrax Immune Globulin: IND submitted

This year, EBS will begin a pivotal trial in 105 healthy volunteers. Emergent BioSolutions Inc. (EBS), Rockville, Md.   Product: Anthrax Immune Globulin (AIG)   Business: Infectious   Molecular target: NA   Description: NA   Indication: Treat symptoms of...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Company News

Cangene, U.S. Department of Health and Human Services infectious news

The U.S. Department of Health and Human Services exercised an option under a 2005 contract with Cangene to purchase 10,000 doses of anthrax immune globulin (AIG) for $143.8 million. The contract permits delivery...
01:22 , Jul 29, 2006 |  BC Extra  |  Company News

Cangene gets $144M anthrax contract

The U.S. Department of Health and Human Services exercised an option under a 2005 contract with Cangene (TSX:CNJ) to purchase 10,000 doses of anthrax immune globulin (AIG) for $143.8 million. The contract permits delivery of...